Barclays Cuts Xylem (XYL) Price Target to $139

Barclays has maintained its Overweight rating on Xylem Inc. with a new price target of $139.0, a 34.07% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:18 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Barclays cut its price target on Xylem Inc. ($XYL) to $139 from $159 on October 13, 2026, and rates the stock "Overweight".

Since the rating, $XYL is up 1.5% to date (from the $102.54 close on Oct 13, 2026).

XYL Xylem Inc.

$104.05 -23.27% year to date

Daily close · Oct 16, 2026

Key Points

On October 13, 2026, Barclays reiterated its Overweight rating on Xylem Inc. (NYSE: XYL) with a price target of $139.0, down from $159.0.
Barclays's $139 price target implies 34.07% upside from Xylem Inc.'s ($XYL) current $103.68 share price.
As of October 16, 2026, Xylem shares were recently trading at $103.68, which is about 25.4% below Barclays' target.
Xylem has a dividend yield of 1.72% and is expected to report its next earnings on November 3, 2026.

Get $XYL trade alerts by text

We text you when insiders, Congress or big funds trade $XYL. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Xylem Inc. alert may contain errors. Disclosures

Barclays has reiterated its Overweight rating on Xylem Inc. (NYSE: XYL) on October 13, 2026, with a new price target of $139.0, down from $159.0. This rating suggests that Barclays believes the stock is likely to perform better than the market average in the near future.

Xylem was recently trading at $103.68 as of October 16, 2026, which places it about 25.4% below Barclays' target price. This indicates that there could be significant upside potential based on the firm's assessment.

Other Institutional Activity in Xylem

Several other institutional investors have adjusted their stakes in Xylem. Blackrock Inc. reduced its holdings by 615,686 shares, bringing its total to about 25 million shares valued at around $2.6 billion. Vanguard Capital Management LLC also cut its stake by 283,116 shares, now holding approximately 15.5 million shares worth about $1.6 billion. State Street Corporation, however, increased its holdings by 271,508 shares, ending with about 11.4 million shares valued at approximately $1.2 billion.

Xylem Inc. Stock Down 3.6%

Xylem shares are currently trading below the recent price target set by Barclays. The stock's recent price of $103.68 shows it is well below the target, highlighting potential for growth if the firm's outlook holds true.

12-month forecast

$XYL price target

Xylem Inc. daily closes and this analyst's $139 target. Not advice.

Recent Earnings

In its most recent earnings report, Xylem posted a revenue of approximately $9.13 billion and an EPS of $4.19. The company has a net margin of 11.2% and a return on equity of 9.2%. The next earnings report is scheduled for November 3, 2026.

Dividend

Xylem pays an annual dividend of $1.72 per share, which translates to a yield of about 1.72%. The company's payout ratio stands at 39.5%.

Insider Buying and Selling at Xylem Inc.

Insider activity at Xylem includes Jerome A. Peribere, a director, who bought 1,210 shares on May 4, 2026, at an average price of $116.61, totaling about $141,098. Meanwhile, Victoria D. Harker sold 1,700 shares on November 4, 2025, at an average price of $148.14, worth about $251,838.

Analysts Set New Price Targets

On October 12, 2026, Citigroup maintained a Buy rating on Xylem with a target of $148.0, down from $172.0. Earlier, on August 24, 2026, Jefferies also maintained a Buy rating with a target of $150.0, up from $145.0. The consensus among analysts suggests a positive outlook for Xylem, with a mean target price that reflects strong potential upside from current levels.

About Xylem

Xylem Inc. designs and manufactures products and solutions for water management across various sectors, including utilities and industrial markets. With a focus on innovation, Xylem aims to address global water challenges. The recent reiteration of Barclays' Overweight rating reflects confidence in Xylem's ability to navigate market conditions effectively.

Bottom Line

Investors should keep an eye on Xylem as it approaches its next earnings date on November 3, 2026. The firm continues to attract attention from analysts, with Barclays' recent rating maintaining a positive outlook despite the revised price target.